These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31941374)

  • 1. An overview of lantibiotic biosynthetic machinery promiscuity and its impact on antimicrobial discovery.
    Sandiford SK
    Expert Opin Drug Discov; 2020 Mar; 15(3):373-382. PubMed ID: 31941374
    [No Abstract]   [Full Text] [Related]  

  • 2. Perspectives on lantibiotic discovery - where have we failed and what improvements are required?
    Sandiford SK
    Expert Opin Drug Discov; 2015 Apr; 10(4):315-20. PubMed ID: 25697059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioengineering of the model lantibiotic nisin.
    Field D; Cotter PD; Ross RP; Hill C
    Bioengineered; 2015; 6(4):187-92. PubMed ID: 25970137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome database mining for the discovery of novel lantibiotics.
    Sandiford SK
    Expert Opin Drug Discov; 2017 May; 12(5):489-495. PubMed ID: 28306363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lantibiotics: promising candidates for future applications in health care.
    Dischinger J; Basi Chipalu S; Bierbaum G
    Int J Med Microbiol; 2014 Jan; 304(1):51-62. PubMed ID: 24210177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing the success rate of lantibiotic drug discovery by Synthetic Biology.
    Montalbán-López M; Zhou L; Buivydas A; van Heel AJ; Kuipers OP
    Expert Opin Drug Discov; 2012 Aug; 7(8):695-709. PubMed ID: 22680308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multipronged approach for engineering novel peptide analogues of existing lantibiotics.
    Escano J; Smith L
    Expert Opin Drug Discov; 2015; 10(8):857-70. PubMed ID: 26004576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commercial development and application of type A lantibiotics.
    Wilson-Stanford S; Smith L
    Recent Pat Antiinfect Drug Discov; 2011 May; 6(2):175-85. PubMed ID: 21517737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating the importance of charged residues in lantibiotics.
    Suda S; Hill C; Cotter PD; Ross RP
    Bioeng Bugs; 2010; 1(5):345-51. PubMed ID: 21326835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving the attrition rate of Lanthipeptide discovery for commercial applications.
    Geng M; Smith L
    Expert Opin Drug Discov; 2018 Feb; 13(2):155-167. PubMed ID: 29195488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the Antimicrobial Peptide Penisin, a Class Ia Novel Lantibiotic from Paenibacillus sp. Strain A3.
    Baindara P; Chaudhry V; Mittal G; Liao LM; Matos CO; Khatri N; Franco OL; Patil PB; Korpole S
    Antimicrob Agents Chemother; 2016 Jan; 60(1):580-91. PubMed ID: 26574006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lantibiotics: mode of action, biosynthesis and bioengineering.
    Bierbaum G; Sahl HG
    Curr Pharm Biotechnol; 2009 Jan; 10(1):2-18. PubMed ID: 19149587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Employing the promiscuity of lantibiotic biosynthetic machineries to produce novel antimicrobials.
    Montalbán-López M; van Heel AJ; Kuipers OP
    FEMS Microbiol Rev; 2017 Jan; 41(1):5-18. PubMed ID: 27591436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of Gut-Derived Nisin-like Lantibiotics against Human Gut Pathogens and Commensals.
    Zhang ZJ; Wu C; Moreira R; Dorantes D; Pappas T; Sundararajan A; Lin H; Pamer EG; van der Donk WA
    ACS Chem Biol; 2024 Feb; 19(2):357-369. PubMed ID: 38293740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lantibiotics produced by Actinobacteria and their potential applications (a review).
    Gomes KM; Duarte RS; de Freire Bastos MDC
    Microbiology (Reading); 2017 Feb; 163(2):109-121. PubMed ID: 28270262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current developments in lantibiotic discovery for treating Clostridium difficile infection.
    Sandiford SK
    Expert Opin Drug Discov; 2019 Jan; 14(1):71-79. PubMed ID: 30479173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methodologies and strategies for the bioengineering of lantibiotics.
    Nagao J; Nishie M; Sonomot K
    Curr Pharm Biotechnol; 2011 Aug; 12(8):1221-30. PubMed ID: 21470152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lantibiotics: insight and foresight for new paradigm.
    Nagao J; Asaduzzaman SM; Aso Y; Okuda K; Nakayama J; Sonomoto K
    J Biosci Bioeng; 2006 Sep; 102(3):139-49. PubMed ID: 17046525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Analysis of Mutacin B-Ny266, a Lantibiotic Active against Caries Pathogens.
    Dufour D; Barbour A; Chan Y; Cheng M; Rahman T; Thorburn M; Stewart C; Finer Y; Gong SG; Lévesque CM
    J Bacteriol; 2020 May; 202(12):. PubMed ID: 32229530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lantibiotics].
    Israil A
    Bacteriol Virusol Parazitol Epidemiol; 1992; 37(3-4):1-8. PubMed ID: 1340251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.